Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement by tumor cell vaccines engineered to express ICOS ligand enhanced antitumor immune responses in both quantity and quality and significantly improved rejection of established melanoma and prostate cancer in mice. This study provides strong support for the development of combinatorial therapies incorporating anti-CTLA-4 and ICOS engagement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the immune monitoring studies performed on the trial highlighted the reverse translational approach and identified ICOS + CD4 T cells as a novel subset of T cells associated with anti-CTLA4 therapy (17,18,171,172).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [172]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“ICOS is a T cell–specific molecule that belongs to the CD28/CTLA-4 family (Hutloff et al., 1999; Sharpe and Freeman, 2002).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Ipilimumab was the first therapy of any kind to show a survival benefit in phase III trials (Hodi et al., 2010; Robert et al., 2011) for patients with advanced melanoma and was approved in March 2011 by the Food and Drug Administration (FDA) as both first and second line therapy for the treatment…”
BackgroundNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“ELISA of tissue culture supernatant from these cells failed to show the presence of soluble/ (nivolumab) in metastatic melanoma showed an objective response rate of 50% (Wolchok et al., 2013).”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 2×
“In a presurgical clinical trial in which patients with localized bladder cancer were treated with ipilimumab, the frequency of T cells expressing inducible co-stimulator (ICOS) was significantly increased both in tumor tissues and peripheral blood of patients (Liakou et al., 2008).”
BackgroundSelf-citationCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“…we showed that inhibitory signals mediated by CTLA-4 were responsible for limiting antitumor responses in a series of mouse models because administration of antibodies blocking the interaction of CTLA-4 with its ligands could result in tumor rejection and long-lived immunity (Leach et al., 1996).”
BackgroundSelf-citationCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“CD28 co-stimulation is subject to down-regulation by inhibitory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4; Walunas et al., 1994; Krummel and Allison, 1995).”
BackgroundSharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712 · cited 2×
“ICOS is a T cell–specific molecule that belongs to the CD28/CTLA-4 family (Hutloff et al., 1999; Sharpe and Freeman, 2002).”
BackgroundHarding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,559 · cited 1×
“Early T cell activation requires an antigen-specific signal mediated by the TCR plus additional costimulatory signals generated by engagement of molecules such as CD28 with their ligands (Harding et al., 1992).”
BackgroundSelf-citationICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Cited by
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
“Anti-ICOS antibodies are expected to enter into clinical trials in 2015.”
BackgroundInfluentialSelf-citationDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Self-citationCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Metadata
- Authors
- Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University College London (GB)
- Ludwig Center for Cancer Immunotherapy 4 , 5 , and 6
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- Allison, James P.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-03-31
- Volume
- 211
- Issue
- 4
- Pages
- 715-725
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3978270
- OpenAlex
- W2157041114
- Cited by
- 300
- References
- 28
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 15 · 2023: 26 · 2022: 22 · 2021: 30 · 2020: 31 · 2019: 36 · 2018: 32 · 2017: 27 · 2016: 23 · 2015: 21 · 2014: 8
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- National Cancer Institute (R01CA163793, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CTLA-4 blockade, ICOS ligand, cancer immunotherapy, melanoma, prostate cancer, tumor cell vaccine, antitumor immunity, combination therapy, immune checkpoint blockade
- MeSH terms
- Animals, Antibodies, Monoclonal, Disease Models, Animal, Immunologic Memory, Immunosuppression Therapy, Immunotherapy, Ligands, Male, Melanoma, Experimental, Prostatic Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Up-Regulation, Cytokines, Lymphocytes, Tumor-Infiltrating, Antigen Presentation, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. https://app.cochat.ai/papers/10.1084/jem.20130590
- The paper
- Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014). Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20130590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.